ISEE - IVERIC bio, Inc.
| Previous Close | 4.3000 |
| Open | 4.4800 |
| Bid | 4.4000 x 3100 |
| Ask | 4.4900 x 900 |
| Day's Range | 4.0603 - 4.5000 |
| 52 Week Range | 0.9060 - 4.5000 |
| Volume | 1,986,246 |
| Avg. Volume | 1,561,101 |
| Market Cap | 181.294M |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | 2.88 |
| EPS (TTM) | 1.5270 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.48 |
- Business Wire
IVERIC bio, Inc. Announces Pricing of Public Offering of Common Stock
IVERIC announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $4.000 per share.
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- Business Wire
IVERIC bio, Inc. Announces Proposed Offering of Common Stock
IVERIC bio announced that it is commencing an underwritten public offering of shares of its common stock.
- Business Wire
IVERIC bio to Present at Evercore ISI 2nd Annual HealthCONx Conference
IVERIC bio, Inc. (ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Evercore ISI 2nd Annual HealthCONx Conference in Boston on Tuesday, December 3, 2019 at 9:50 a.m. Eastern Time. Investors and the general public are invited to listen to a live webcast of the presentation on the Investor / Events & Presentations section of the IVERIC bio website at www.ivericbio.com. An archived replay of the webcast will be available on the Company’s website immediately following the conference and for at least two weeks thereafter.
- Business Wire
IVERIC bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapy
Dr. Gao brings over 30 years of scientific research experience in gene-based treatments. As one of the world’s leading gene therapy experts, Dr. Gao’s highly distinguished career includes major contributions to the development of adeno-associated virus (AAV) gene delivery technology. Dr. Gao is the current President of the American Society of Gene and Cell Therapy (ASGCT).
- Business Wire
IVERIC bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019
- Live Webcast to Begin at 8:00 a.m. Eastern Time -
- Zacks
IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
- Business Wire
IVERIC bio Reports Third Quarter 2019 Operational Highlights and Financial Results
- Conference Call and Webcast Today, November 12, 2019, at 8:00 a.m. ET -
- Business Wire
IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled
IVERIC bio, Inc. (ISEE) today provided further clinical details and its development strategy for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Based on the study design and the robustness of the recently announced topline data from a randomized, double masked, sham controlled Zimura clinical trial, the Company believes that only one additional pivotal, randomized, double masked, sham controlled clinical trial would potentially be needed to demonstrate the safety and efficacy of Zimura in GA secondary to dry AMD in a manner sufficient to support regulatory approval, assuming that Zimura’s safety and efficacy profile remains consistent with the findings observed to date and subject to regulatory review.
- Business Wire
IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio, Inc. (ISEE) today reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company’s common stock. In addition, on November 1, 2019, the Company granted Dr. Scaria 50,000 restricted stock units for shares of the Company’s common stock.
- Business Wire
IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
- Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 -
- Business Wire
IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer
Dr. Scaria will lead the Company’s research and pre-clinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi and most recently at Casebia Therapeutics, leading multiple ocular gene therapy programs.
- Business Wire
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Overall Data Suggest a Dose Response Relationship Across Treatment Groups -
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For IVERIC bio, Inc. (NASDAQ:ISEE)?
If you're interested in IVERIC bio, Inc. (NASDAQ:ISEE), then you might want to consider its beta (a measure of share...
- PR Newswire
Lifshitz & Miller LLP Announces Investigation of Allegiant Travel Company, AMC Entertainment Holdings, Inc., Aqua Metals, Inc., CenturyLink, Inc., IVERIC bio, Inc., and Teva Pharmaceutical Industries Ltd.
NEW YORK , Oct. 13, 2019 /PRNewswire/ -- Allegiant Travel Company (ALGT) Lifshitz & Miller announces investigation into possible securities laws in connection with a CBS News 60 Minutes segment criticizing ...
- Business Wire
Kaskela Law LLC Announces Investigation of IVERIC bio, Inc. on Behalf of Stockholders
Kaskela Law LLC has commenced an investigation of IVERIC bio, Inc. , formerly known as Ophthotech Corp., on behalf of the Company’s stockholders.
- Business Wire
CORRECTING and REPLACING IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
In the first sentence of the release, the date and time should read: Monday, October 7, 2019 at 8:00 a.m. Eastern Time (instead of: Monday, October 7, 2019 at 8:30 a.m. Eastern Time). IVERIC bio, Inc. (ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference in New York on Monday, October 7, 2019 at 8:00 a.m. Eastern Time.
- PR Newswire
Johnson Fistel, LLP Announces Investigations of Trevena, Inc. and IVERIC bio, Inc.; Long Term Investors Encouraged to Contact the Firm
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Trevena, Inc. (TRVN) ('' Trevena ''). Last year, a class action complaint was filed against Trevena and certain of its officers and directors.
- Zacks
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
